1992-24-1

Basic information

• Product Name: Acetamide, N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-
• CAS NO: 1992-24-1
• Molecular Formula: C11H9F6NO2
• Molecular Weight: 301.188
• Mol File: 1992-24-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-(1992-24-1)
• EPA Substance Registry System: Acetamide, N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-(1992-24-1)

Safety Data

• Hazardous Substances Data: 1992-24-1(Hazardous Substances Data)

Upstream product

• 722-92-9 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 108-24-7 acetic anhydride 

Downstream Products

• 65797-85-5 2-(4-ethylamino-phenyl)-1,1,1,3,3,3-hexafluoro-propan-2-ol 
• 872690-44-3 2-[4-(benzyl-ethyl-amino)-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol 
• 872690-52-3 2-{4-[ethyl-(thiazol-4-ylmethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol 
• 872690-50-1 2-[4-(ethyl-phenethyl-amino)-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol 
• 872690-77-2 2-(4-{[2-(3-chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-ethyl-amino}-phenyl)-1,1,1,3,3,3-hexafluoro-propan-2-ol 
• 872690-76-1 2-(4-{ethyl-[5-methyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-amino}-phenyl)-1,1,1,3,3,3-hexafluoro-propan-2-ol 
• 872690-45-4 N-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-acetamide 

Relevant articles and documents

Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β

A series of branched and unbranched anilinohexafluoroisopropanols related to the known sulfonamide T0901317 were prepared and evaluated as activators/modulators of both LXRα and LXRβ. A structure-activity relationship was established and compounds with high potency on both the receptors were identified. Many compounds showed a tendency toward selectivity for LXRβ versus LXRα. Several analogues were evaluated for effects on plasma lipoprotein levels in mice. A few of these significantly raised HDL-cholesterol levels in plasma but showed markedly different effects on liver triglyceride content, suggesting that this series may yield candidates with improved efficacy/safety profiles compared to existing molecules.